Hemostemix Inc.
HEM
Clasificación en acciones
#32862
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Precio por acción
$0.04036653
Capitalización bursátil
$8.54M
Cambio (1 día)
0.00%
Cambio (1 año)
-44.48%
País
CA
Comercio Hemostemix Inc. (HEM)
Categoría
Healthcare
Ratio P/S de Hemostemix Inc. (HEM)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Hemostemix Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Hemostemix Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
